Literature DB >> 27573425

IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal.

Christian B Gocke1, Ross McMillan1, Qiuju Wang1, Asma Begum1, Vesselin R Penchev1, Syed A Ali1, Ivan Borrello1, Carol Ann Huff1, William Matsui2.   

Abstract

Despite improved outcomes in newly diagnosed multiple myeloma, virtually all patients relapse and ultimately develop drug-resistant disease. Aberrant RAS/MAPK signaling is activated in the majority of relapsed/refractory multiple myeloma patients, but its biological consequences are not fully understood. Self-renewal, as defined by the long-term maintenance of clonogenic growth, is essential for disease relapse, and we examined the role of RAS/MAPK activation on multiple myeloma self-renewal by targeting IQ motif-containing GTPase-activating protein 1 (IQGAP1), an intracellular scaffold protein required for mutant RAS signaling. We found that loss of IQGAP1 expression decreased MAPK signaling, cell-cycle progression, and tumor colony formation. Similarly, a peptide mimicking the WW domain of IQGAP1 that interacts with ERK inhibited the clonogenic growth and self-renewal of multiple myeloma cell lines and primary clinical specimens in vitro as well as tumor-initiating cell frequency in immunodeficient mice. During multiple myeloma progression, self-renewal may be enhanced by aberrant RAS/MAPK signaling and inhibited by targeting IQGAP1. Mol Cancer Ther; 15(11); 2733-9. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27573425      PMCID: PMC5097000          DOI: 10.1158/1535-7163.MCT-16-0323

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  47 in total

1.  Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations.

Authors:  I Hanamura; Y Huang; F Zhan; B Barlogie; J Shaughnessy
Journal:  Leukemia       Date:  2006-05-11       Impact factor: 11.528

2.  Clinical and biological significance of RAS mutations in multiple myeloma.

Authors:  W J Chng; N Gonzalez-Paz; T Price-Troska; S Jacobus; S V Rajkumar; M M Oken; R A Kyle; K J Henderson; S Van Wier; P Greipp; B Van Ness; R Fonseca
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

3.  Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.

Authors:  D Billadeau; P Liu; D Jelinek; N Shah; T W LeBien; B Van Ness
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

4.  NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.

Authors:  Zohar Sachs; Rebecca S LaRue; Hanh T Nguyen; Karen Sachs; Klara E Noble; Nurul Azyan Mohd Hassan; Ernesto Diaz-Flores; Susan K Rathe; Aaron L Sarver; Sean C Bendall; Ngoc A Ha; Miechaleen D Diers; Garry P Nolan; Kevin M Shannon; David A Largaespada
Journal:  Blood       Date:  2014-10-14       Impact factor: 22.113

5.  IQGAP1 is a scaffold for mitogen-activated protein kinase signaling.

Authors:  Monideepa Roy; Zhigang Li; David B Sacks
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

6.  Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.

Authors:  Thomas Rasmussen; Michael Kuehl; Marianne Lodahl; Hans E Johnsen; Inger Marie S Dahl
Journal:  Blood       Date:  2004-08-31       Impact factor: 22.113

7.  IQGAP1 binds ERK2 and modulates its activity.

Authors:  Monideepa Roy; Zhigang Li; David B Sacks
Journal:  J Biol Chem       Date:  2004-02-17       Impact factor: 5.157

8.  Overexpression of IQGAP1 in human pancreatic cancer.

Authors:  Xiao-Xia Wang; Xiao-Zhong Li; Li-Qin Zhai; Zhi-Rong Liu; Xian-Jiu Chen; Yi Pei
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2013-10

9.  Inhibiting MEK in MAPK pathway-activated myeloma.

Authors:  C J Heuck; Y Jethava; R Khan; F van Rhee; M Zangari; S Chavan; K Robbins; S E Miller; A Matin; M Mohan; S M Ali; P J Stephens; J S Ross; V A Miller; F Davies; B Barlogie; G Morgan
Journal:  Leukemia       Date:  2015-07-31       Impact factor: 11.528

10.  Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.

Authors:  Natacha Bohin; Tiffany Wen; Qing Li; Victor Ng; Jeffrey Magee; Shann-Ching Chen; Kevin Shannon; Sean J Morrison
Journal:  Nature       Date:  2013-11-27       Impact factor: 49.962

View more
  3 in total

1.  IQGAP1 Maintains Pancreatic Ductal Adenocarcinoma Clonogenic Growth and Metastasis.

Authors:  Joey H Li; Ross H McMillan; Asma Begum; Christian B Gocke; William Matsui
Journal:  Pancreas       Date:  2019-01       Impact factor: 3.327

2.  Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination.

Authors:  Juan-Jose Garcés; Michal Simicek; Marco Vicari; Lucie Brozova; Leire Burgos; Renata Bezdekova; Diego Alignani; Maria-Jose Calasanz; Katerina Growkova; Ibai Goicoechea; Xabier Agirre; Ludek Pour; Felipe Prosper; Rafael Rios; Joaquin Martinez-Lopez; Pamela Millacoy; Luis Palomera; Rafael Del Orbe; Albert Perez-Montaña; Sonia Garate; Laura Blanco; Marta Lasa; Patricia Maiso; Juan Flores-Montero; Luzalba Sanoja-Flores; Zuzana Chyra; Alexander Vdovin; Tereza Sevcikova; Tomas Jelinek; Cirino Botta; Halima El Omri; Jonathan Keats; Alberto Orfao; Roman Hajek; Jesus F San-Miguel; Bruno Paiva
Journal:  Leukemia       Date:  2019-10-08       Impact factor: 11.528

3.  Widespread intronic polyadenylation diversifies immune cell transcriptomes.

Authors:  Irtisha Singh; Shih-Han Lee; Adam S Sperling; Mehmet K Samur; Yu-Tzu Tai; Mariateresa Fulciniti; Nikhil C Munshi; Christine Mayr; Christina S Leslie
Journal:  Nat Commun       Date:  2018-04-30       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.